Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.

Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, Graham I, Dekker CL, Ho D, Winokur P, Walter E, Bennet J, Formica N, Hartel G, Skeljo M, Edwards KM.

Vaccine. 2008 Jul 29;26(32):4057-61. doi: 10.1016/j.vaccine.2008.05.024. Epub 2008 Jun 2.

2.

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.

Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.

BMC Infect Dis. 2013 Jul 24;13:343. doi: 10.1186/1471-2334-13-343.

3.

Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.

Vinnemeier CD, Fischer-Herr J, Meyer S, Liebig K, Theeß W, Burchard GD, Cramer JP.

Hum Vaccin Immunother. 2014;10(2):441-8. doi: 10.4161/hv.27140. Epub 2013 Nov 15.

4.

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.

Tsurudome Y, Kimachi K, Okada Y, Matsuura K, Ooyama Y, Ibaragi K, Kino Y, Ueda K.

Microbiol Immunol. 2015 Oct;59(10):597-604. doi: 10.1111/1348-0421.12316.

5.

Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety.

Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, Cohen C, Valette M, Cutland CL, Sanne I.

Clin Infect Dis. 2011 Jan 1;52(1):128-37. doi: 10.1093/cid/ciq004.

PMID:
21148531
6.

The effect of age and recent influenza vaccination history on the immunogenicity and efficacy of 2009-10 seasonal trivalent inactivated influenza vaccination in children.

Ng S, Ip DK, Fang VJ, Chan KH, Chiu SS, Leung GM, Peiris JS, Cowling BJ.

PLoS One. 2013;8(3):e59077. doi: 10.1371/journal.pone.0059077. Epub 2013 Mar 12.

7.

A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.

Roggelin L, Vinnemeier CD, Meyer S, Witte K, Marx L, Theeß W, Burchard GD, Rolling T, Cramer JP.

Hum Vaccin Immunother. 2015;11(10):2370-5. doi: 10.1080/21645515.2015.1064570.

8.

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B; CAIV-T Asthma Study Group.

Pediatr Infect Dis J. 2006 Oct;25(10):860-9.

PMID:
17006278
9.

Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.

Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.

Pediatr Infect Dis J. 2012 May;31(5):494-500. doi: 10.1097/INF.0b013e31824bb179.

PMID:
22301476
10.

A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.

Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.

J Infect Dis. 2013 Jun 15;207(12):1878-87. doi: 10.1093/infdis/jit091. Epub 2013 Mar 7.

11.

Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector.

Simon JK, Carter M, Pasetti MF, Sztein MB, Kotloff KL, Weniger BG, Campbell JD, Levine MM.

Vaccine. 2011 Nov 28;29(51):9544-50. doi: 10.1016/j.vaccine.2011.09.097. Epub 2011 Oct 8.

PMID:
21986218
12.

Safety and immunogenicity of a new trivalent inactivated split-virus influenza vaccine in healthy Korean children: a randomized, double-blinded, active-controlled, phase III study.

Kang JH, Oh CE, Lee J, Lee SY, Cha SH, Kim DS, Kim HH, Lee JH, Kim JT, Ma SH, Hong YJ, Cheong HJ, Lee HJ.

J Korean Med Sci. 2011 Nov;26(11):1421-7. doi: 10.3346/jkms.2011.26.11.1421. Epub 2011 Oct 27.

13.

Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.

Madhi SA, Dittmer S, Kuwanda L, Venter M, Cassim H, Lazarus E, Thomas T, Liberty A, Treurnich F, Cutland CL, Weinberg A, Violari A.

AIDS. 2013 Jan 28;27(3):369-79. doi: 10.1097/QAD.0b013e32835ab5b2.

PMID:
23032417
14.

A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial.

Vajo Z, Tamas F, Jankovics I.

Clin Vaccine Immunol. 2012 Mar;19(3):313-8. doi: 10.1128/CVI.05619-11. Epub 2012 Jan 4.

15.

Phase IV: randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adults.

Song JY, Cheong HJ, Lee J, Wie SH, Park KH, Kee SY, Jeong HW, Kim YS, Noh JY, Choi WS, Park DW, Sohn JW, Kim WJ.

Hum Vaccin Immunother. 2014;10(10):2958-64. doi: 10.4161/21645515.2014.970950. Epub 2014 Nov 19.

16.

A randomized, controlled, blinded study of the safety, immunogenicity and batch consistency of Aleph inactivated split influenza vaccine made in China in Chinese people.

Li S, Li L, Ai X, Yang L, Bai Y, Wang Z, Han H, Lu Q, Luo F, Zhang Z, Liu C, Xiao J, Shi N.

Hum Vaccin Immunother. 2014;10(3):557-65. Epub 2013 Dec 3.

17.

Immunogenicity and safety of three 2010-2011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adults: a double-blind and randomized trial.

Luo FJ, Yang LQ, Ai X, Bai YH, Wu J, Li SM, Zhang Z, Lu M, Li L, Wang ZY, Shi NM.

Hum Vaccin Immunother. 2013 Aug;9(8):1725-34. doi: 10.4161/hv.24832. Epub 2013 Jun 4.

18.

Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial.

Kang K, Han S, Hong T, Jeon S, Paek J, Kang JH, Yim DS.

Yonsei Med J. 2016 Nov;57(6):1354-60. doi: 10.3349/ymj.2016.57.6.1354.

19.

Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.

Englund JA, Walter E, Black S, Blatter M, Nyberg J, Ruben FL, Decker MD; GRC28 Study Team.

Pediatr Infect Dis J. 2010 Feb;29(2):105-10. doi: 10.1097/INF.0b013e3181b84c34.

PMID:
19934787
20.

Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?

Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.

Pediatrics. 2006 Sep;118(3):e570-8.

PMID:
16950948

Supplemental Content

Support Center